Adia Nutrition Secures Lease for First Clinic in Winter Park, Florida
29. Oktober 2024 09:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition Inc. proudly announces the signed lease for their state-of-the-art clinic, set to open in the distinguished Winter Park Medical...
Trethera Announces Presentation at the Rare Neuroimmune Disorders Symposium Annual Meeting
15. Oktober 2024 11:48 ET
|
Trethera Corporation
LOS ANGELES, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Adia Nutrition Inc. Takes Major Steps Forward: Signs LOI for First Clinic and Engages Legal Expertise for Licensing
15. Oktober 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is proud to announce a groundbreaking initiative in the fight against Multiple Sclerosis (MS) with the signing of...
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion
17. September 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the hiring of a prominent Winter Springs law firm to fortify its intellectual property...
ADIA Nutrition Appoints Dr. Richard Edwards, DO as Second Medical Director
10. September 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is excited to announce the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards...
Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board
05. September 2023 10:55 ET
|
Trethera Corporation
LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
14. August 2023 11:23 ET
|
Trethera Corporation
LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Trethera Announces Appointment of Laurent Dubois to Board of Directors
15. Februar 2023 10:32 ET
|
Trethera Corporation
LOS ANGELES, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
24. Januar 2023 12:12 ET
|
Trethera Corporation
LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors
18. Januar 2023 12:37 ET
|
Trethera Corporation
LOS ANGELES, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...